A meta‐analysis of RCTs of GLP‐1 therapies and pancreatitis found no significant increase in risk across a range of comparators (Mantel‐Haenszel [M‐H] OR, 0.93 [95% CI, 0.65‐1.34]).19 A sub‐group analysis including only trials with adjudication of AP had similar results (M‐H OR, 0.87 [95% CI, −0.53‐1.44]). The gene discussed is GCG; the disease is pancreatitis.